CN108634303A - It is a kind of prevent, the product and preparation method thereof of auxiliary treatment disease of eye - Google Patents

It is a kind of prevent, the product and preparation method thereof of auxiliary treatment disease of eye Download PDF

Info

Publication number
CN108634303A
CN108634303A CN201810460967.6A CN201810460967A CN108634303A CN 108634303 A CN108634303 A CN 108634303A CN 201810460967 A CN201810460967 A CN 201810460967A CN 108634303 A CN108634303 A CN 108634303A
Authority
CN
China
Prior art keywords
parts
portions
vitamin
mass fraction
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810460967.6A
Other languages
Chinese (zh)
Inventor
王宁利
杨宗鑫
陈春辉
张正挺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Xinwei Low Carbon Technology R & D Co Ltd
Original Assignee
Hangzhou Xinwei Low Carbon Technology R & D Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Xinwei Low Carbon Technology R & D Co Ltd filed Critical Hangzhou Xinwei Low Carbon Technology R & D Co Ltd
Priority to CN201810460967.6A priority Critical patent/CN108634303A/en
Publication of CN108634303A publication Critical patent/CN108634303A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

It is disclosed by the invention be it is a kind of prevent, the product and preparation method thereof of auxiliary treatment disease of eye, include following component by mass fraction product：1 2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 40 parts of lutein, 0.05 4 parts of zeaxanthin, 1 70 parts of mono maple nervonic acid, 1 300 parts of anthocyanin, 0.5 200 parts of wolfberry fruit extract, 0 100 parts of mannitol, 0.1 100 parts of vitamin C, 0.02 0.3 parts of vitamin A, 0.5 6 parts of zinc agent, above-mentioned functional component is mixed and can be made into drops through particular dosage form technique, patch, pulvis, lozenge, oral solution, simple production process of the present invention, including a variety of dosage forms, it is easy to use, absorption of human body utilization rate is high, have the effect of good prevention and treatment and auxiliary treatment to most of disease of eye.

Description

It is a kind of prevent, the product and preparation method thereof of auxiliary treatment disease of eye
Technical field
The present invention relates to a kind of prevention, the products and preparation method thereof of adjuvant treatment of diseases, more specifically say, are related to one Kind prevent, the product and preparation method thereof of auxiliary treatment disease of eye.
Background technology
With universal and the age the growth of the electronic products such as TV, computer, IPad, mobile phone, people suffer from various eye disease Also rapid increase, these disease of eye bring the change of vision to probability mostly therewith, metamorphopsia, discoloration such as occur, at the moment secretly Point, visual impairment, severe patient can cause to blind, to cause huge threat to quality of life.
At least tens of kinds of disease of eye, it is most common to have myopia, long sight, presbyopic, astigmatism, xerophthalmia, maculopathy, sugar Net, cataract, visual fatigue etc..Currently, eye illness control present situation allows of no optimist both at home and abroad, according to incompletely statistics, China is white Cataract or glaucoma patient is more than 5 million peoples, and about 1 million people of glaucoma patient, especially in recent years, young people start to become huge blueness Light eye patient population.
The present invention is with water-soluble Astaxanthin In Haematococcus Pluvialis powder, lutein, zeaxanthin, mono maple nervonic acid, anthocyanin, Chinese holly Qi extract, mannitol, vitamin C, vitamin A, zinc agent are functional component, prepare a kind of disease of eye that prevents, treats Product, it can prevent, treat the disease of eye such as visual fatigue, xerophthalmia, maculopathy, glaucoma and sugar net.
Invention content
In order to solve above-mentioned prior art problem, the present invention, which provides to have, can prevent, treat visual fatigue, xerophthalmia, Huang A kind of prevention of the technical characterstics such as the eyes such as pinta change, glaucoma and sugar net, the product of auxiliary treatment disease of eye.
Another object of the present invention is to provide a kind of prevention, auxiliary with the technical characterstics such as simple, at low cost are made Treat the product preparation method of disease of eye.
To achieve the goals above, the present invention is achieved by the following technical solutions：
It is a kind of prevent, the product of auxiliary treatment disease of eye, by mass fraction, the product includes following component：1-2000 parts Water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-40 parts of lutein, 0.05-4 parts of zeaxanthins, 1-70 parts of mono maple nervonic acids, 1-300 Part anthocyanin, 0.5-200 parts of wolfberry fruit extracts, 0-100 portions of mannitol, 0.1-100 parts of vitamin Cs, 0.02-0.3 parts of vitamins A, the dosage form of 0.5-6 parts of zinc agent, the product includes drops, patch, pulvis, lozenge, oral solution.
As an improvement by mass fraction, the drops includes following component：1-100 parts of water-soluble haematococcus pluvialis shrimps Green element powder, 1-10 parts of lutein, 0.05-2 parts of zeaxanthins, 1-5 parts of mono maple nervonic acids, 1-20 portions of anthocyanin, 0.5-4 parts of Chinese hollys Qi extract, 0-3 portion mannitol, 0.1-2 parts of vitamin Cs, 0.02-0.1 parts of vitamin As, 0.5-2 parts of zinc agent, 1-100 parts of anti-corrosions Agent, 0.01-15 parts of xanthans, 1000-50000 parts of water.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the drops is as follows：
1) mass fraction is pressed, 0.01-15 parts of xanthans, 1-100 portions of preservatives are added in 1000-50000 parts of water, are stirred Mixing is mixed, mixture A is obtained；
2) mass fraction is pressed, by 1-100 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-10 parts of lutein, 0.05-2 parts of jade Cream-coloured matter, 1-5 part mono maple nervonic acid, 1-20 portions of anthocyanin, 0.5-4 parts of wolfberry fruit extracts, 0-3 portions of mannitol, 0.1-2 parts of dimensions C, 0.02-0.1 parts of vitamin As of raw element, 0.5-2 parts of zinc agent are added to step 1) and obtain in mixture A, stir and evenly mix, are mixed Close object B；
3) the mixture B that step 2) obtains sterilized, packing, labelled, obtain drops.
As an improvement by mass fraction, the patch includes following component：1-400 parts of water-soluble haematococcus pluvialis shrimps Green element powder, 1-20 parts of lutein, 0.05-2 parts of zeaxanthins, 1-10 parts of mono maple nervonic acids, 1-30 portions of anthocyanin, 0.5-10 parts Wolfberry fruit extract, 0-10 portion mannitol, 0.1-5 parts of vitamin Cs, 0.02-0.1 parts of vitamin As, 0.5-2 parts of zinc agent, 1-400 parts Preservative, 1-2000 part patch substrate.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the patch is as follows：
1) mass fraction is pressed, by 1-400 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-20 parts of lutein, 0.05-2 parts of jade Cream-coloured matter, 1-10 part mono maple nervonic acid, 1-30 portions of anthocyanin, 0.5-10 parts of wolfberry fruit extracts, 0-10 parts of mannitol, 0.1-5 Part vitamin C, 0.02-0.1 parts of vitamin As, 0.5-2 parts of zinc agent, 1-400 portions of preservatives and 1-2000 parts of patch substrates heat preservations are mixed It closes, obtains mixture C；
2) mass fraction is pressed, step 1), which is obtained mixing C, is applied to back sheet, and is pressed with lid lining, after cutting out, encapsulating Obtain patch.
As an improvement by mass fraction, the pulvis includes following component：1-2000 parts of water-soluble haematococcus pluvialis shrimps Green element powder, 1-40 parts of lutein, 0.05-4 parts of zeaxanthins, 1-70 parts of mono maple nervonic acids, 1-300 parts of anthocyanin, 0.5-200 Part wolfberry fruit extract, 0-100 portions of mannitol, 0.1-100 parts of vitamin Cs, 0.02-0.3 parts of vitamin As, 0.5-6 parts of zinc agent, 10- 5000 parts of soyabean protein powders, 100-45000 parts of soy bean edible fiber powders.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the pulvis is as follows：
1) mass fraction is pressed, by 1-2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-40 parts of lutein, 0.05-4 parts of jade Cream-coloured matter, 1-70 part mono maple nervonic acid, 1-300 portions of anthocyanin, 0.5-200 parts of wolfberry fruit extracts, 0-100 portions of mannitol, 0.1-100 parts of vitamin Cs, 0.02-0.3 parts of vitamin As, 0.5-6 parts of zinc agent stir and evenly mix, and obtain mixture D；
2) mass fraction is pressed, 10-5000 parts of soyabean protein powders, 450-45000 parts of soy bean edible fiber powders are added to step It in the rapid mixture D 1) obtained, stirs and evenly mixs, dry, powder processed obtains pulvis.
As an improvement by mass fraction, the lozenge includes following component：1-800 parts of water-soluble haematococcus pluvialis shrimps Green element powder, 1-20 parts of lutein, 0.05-4 parts of zeaxanthins, 1-40 parts of mono maple nervonic acids, 1-100 parts of anthocyanin, 0.5-100 Part wolfberry fruit extract, 0-50 portions of mannitol, 0.1-60 parts of vitamin Cs, 0.02-0.2 parts of vitamin As, 0.5-4 parts of zinc agent, 0.1- 30 parts of magnesium stearates, 0.05-15 parts of citric acids, 10-4500 parts of D-sorbites, 0.01-10 parts of food flavors.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the lozenge is as follows：
1) mass fraction is pressed, by 1-800 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-20 parts of lutein, 0.05-4 corns Yellow matter part, 1-40 parts of mono maple nervonic acids, 1-100 portions of anthocyanin, 0.5-100 parts of wolfberry fruit extracts, 0-50 parts of mannitol, 0.1- 60 parts of vitamin Cs, 0.02-0.2 parts of vitamin As, 0.5-4 parts of zinc agent, are stirred mixture E；
2) press mass fraction, by 0.1-30 parts of magnesium stearates, 0.05-15 parts of citric acids, 10-4500 parts of D-sorbites, 0.01-10 parts of food flavors are added in the mixture E of step 1) acquisition, are stirred tabletting, obtain lozenge.
As an improvement by mass fraction, the oral solution includes following component：1-2000 parts of water-soluble haematococcus pluvialis Astaxanthin powder, 1-40 part lutein, 0.05-4 parts of zeaxanthins, 1-70 parts of mono maple nervonic acids, 1-150 parts of anthocyanin, 0.5- 100 parts of wolfberry fruit extracts, 0-80 portions of mannitol, 0.1-100 parts of vitamin Cs, 0.02-0.3 parts of vitamin As, 0.5-6 parts of zinc agent, 0.5-750 parts of xanthans, 0.5-750 parts of locust bean gums, 0.5-750 parts of carragheens, 0.25-250 portions of preservatives, 5-1000 portions of foods With essence, 5000-500000 parts of water.
The product and preparation method thereof of a kind of prevention and treatment and auxiliary treatment disease of eye, the preparation step of the oral solution It is rapid as follows：
1) mass fraction is pressed, 0.5-750 parts of xanthans, 0.5-750 parts of locust bean gums, 0.5-750 parts of carragheens are added It into 5000-500000 parts of water, stirs and evenly mixs, obtains mixture F；
2) mass fraction is pressed, by 1-2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-40 parts of lutein, 0.05-4 parts of jade Cream-coloured matter, 1-70 part mono maple nervonic acid, 1-150 portions of anthocyanin, 0.5-100 parts of wolfberry fruit extracts, 0-80 parts of mannitol, 0.1- 100 parts of vitamin Cs, 0.02-0.3 parts of vitamin As, 0.5-6 parts of zinc agent are added in the mixture F of step 1) acquisition, and stirring is mixed It is even, 0.25-250 portions of preservatives, 5-1000 parts of food flavors are added, are stirred and evenly mixed, oral solution is obtained.
Beneficial effects of the present invention：Simple production process of the present invention, easy to use, absorption of human body utilization rate is high；It can prevent And the disease of eye such as treatment visual fatigue, xerophthalmia, maculopathy, glaucoma and sugar net；Preparation flow is simple, it is easy to operate, It can volume production；It has no toxic side effect, there is interests health.
Specific implementation mode
Below by way of specific embodiment, the present invention is further illustrated, but embodiments of the present invention not by The limitation of following embodiment.
Embodiment 1 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component：1 Part water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part of mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of vitamin C, 0.02 part of vitamin A, 0.5 part of zinc agent, the dosage form of the product Including drops, patch, pulvis, lozenge, oral solution.
By mass fraction, the drops includes following component：1 part of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part of mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of dimension life Plain C, 0.02 part of vitamin A, 0.5 part of zinc agent, 1 portion of preservative, 0.01 part of xanthans, 1000 parts of water.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the drops is as follows：
1) mass fraction is pressed, 0.01 part of xanthans, 1 portion of preservative are added in 1000 parts of water, stirs and evenly mixs, is mixed Close object A；
2) press mass fraction, by 1 part of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part Mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of vitamin C, 0.02 part of vitamin A, 0.5 part of zinc agent is added to step 1) and obtains in mixture A, stirs and evenly mixs, and obtains mixture B；
3) the mixture B that step 2) obtains sterilized, packing, labelled, obtain drops.
Embodiment 2 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component： 30 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 2 parts of lutein, 0.2 part of zeaxanthin, 2 parts of mono maple nervonic acids, 5 portions of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.3 part of vitamin C, 0.05 part of vitamin A, 0.8 part of zinc agent, the dosage form of the product Including drops, patch, pulvis, lozenge, oral solution.
By mass fraction, the drops includes following component：30 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 2 parts of lutein, 0.2 part of zeaxanthin, 2 parts of mono maple nervonic acids, 5 portions of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.3 part of vitamin C, 0.05 part of vitamin A, 0.8 part of zinc agent, 15 portions of preservatives, 1.5 parts of xanthans, 10000 parts of water.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the drops is as follows：
1) mass fraction is pressed, 1.5 parts of xanthans, 15 portions of preservatives are added in 10000 parts of water, are stirred and evenly mixed, is obtained Mixture A；
2) press mass fraction, by 30 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 2 parts of lutein, 0.2 part of zeaxanthin, 2 parts Mono maple nervonic acid, 5 portions of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.3 part of vitamin C, 0.05 part of vitamin A, 0.8 part of zinc agent is added to step 1) and obtains in mixture A, stirs and evenly mixs, and obtains mixture B；
3) the mixture B that step 2) obtains sterilized, packing, labelled, obtain drops.
Embodiment 3 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component： 2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 40 parts of lutein, 4 parts of zeaxanthins, 70 parts of mono maple nervonic acids, 300 parts of flowers Color glycosides, 200 parts of wolfberry fruit extracts, 100 portions of mannitol, 100 parts of vitamin Cs, 0.3 part of vitamin A, 6 parts of zinc agent, the product Dosage form includes drops, patch, pulvis, lozenge, oral solution.
By mass fraction, the drops includes following component：100 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 10 parts of leaf Huangs Element, 2 parts of zeaxanthins, 5 parts of mono maple nervonic acids, 20 portions of anthocyanin, 4 parts of wolfberry fruit extracts, 3 portions of mannitol, 2 parts of vitamin Cs, 0.1 part of vitamin A, 2 parts of zinc agent, 100 portions of preservatives, 15 parts of xanthans, 50000 parts of water.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the drops is as follows：
1) mass fraction is pressed, 15 parts of xanthans, 100 portions of preservatives are added in 50000 parts of water, are stirred and evenly mixed, is obtained Mixture A；
2) press mass fraction, by 100 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 10 parts of lutein, 2 parts of zeaxanthins, 5 parts Mono maple nervonic acid, 20 portions of anthocyanin, 4 parts of wolfberry fruit extracts, 3 portions of mannitol, 2 parts of vitamin Cs, 0.1 part of vitamin A, 2 parts of zinc Agent is added to step 1) and obtains in mixture A, stirs and evenly mixs, and obtains mixture B；
3) the mixture B that step 2) obtains sterilized, packing, labelled, obtain drops.
Embodiment 4 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component：1 Part water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part of mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of vitamin C, 0.02 part of vitamin A, 0.5 part of zinc agent, the dosage form of the product Including drops, patch, pulvis, lozenge, oral solution.
By mass fraction, the patch includes following component：1 part of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part of mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of dimension life Plain C, 0.02 part of vitamin A, 0.5 part of zinc agent, 1 portion of preservative, 1 part of patch substrate.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the patch is as follows：
1) press mass fraction, by 1 part of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part Mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 0 portion of mannitol, 0.1-5 parts of vitamin Cs, 0.02 part of vitamin A, 0.5 part of zinc agent, 1 portion of preservative are mixed with 1 part of patch substrate heat preservation, obtain mixture C；
2) mass fraction is pressed, step 1), which is obtained mixing C, is applied to back sheet, and is pressed with lid lining, after cutting out, encapsulating Obtain patch.
Embodiment 5 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component： 10 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part of mono maple nervonic acid, 2 parts of patterns Glycosides, 0.5 part of wolfberry fruit extract, 2 portions of mannitol, 0.2 part of vitamin C, 0.02 part of vitamin A, 0.5 part of zinc agent, the product Dosage form includes drops, patch, pulvis, lozenge, oral solution.
By mass fraction, the patch includes following component：10 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part of mono maple nervonic acid, 2 portions of anthocyanin, 0.5 part of wolfberry fruit extract, 2 portions of mannitol, 0.2 part of dimension life Plain C, 0.02 part of vitamin A, 0.5 part of zinc agent, 1 portion of preservative, 480 parts of patch substrates.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the patch is as follows：
1) mass fraction is pressed, by 10 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 Part mono maple nervonic acid, 2 portions of anthocyanin, 0.5 part of wolfberry fruit extract, 2 portions of mannitol, 0.2 part of vitamin C, 0.02 part of vitamin A, 0.5 part of zinc agent, 1 portion of preservative are mixed with 480 parts of patch substrate heat preservations, obtain mixture C；
2) mass fraction is pressed, step 1), which is obtained mixing C, is applied to back sheet, and is pressed with lid lining, after cutting out, encapsulating Obtain patch.
Embodiment 6 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component： 2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 40 parts of lutein, 4 parts of zeaxanthins, 70 parts of mono maple nervonic acids, 300 parts of flowers Color glycosides, 200 parts of wolfberry fruit extracts, 100 portions of mannitol, 100 parts of vitamin Cs, 0.3 part of vitamin A, 6 parts of zinc agent, the product Dosage form includes drops, patch, pulvis, lozenge, oral solution.
By mass fraction, the patch includes following component：2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 40 parts of leaf Huangs Element, 4 parts of zeaxanthins, 70 parts of mono maple nervonic acids, 300 portions of anthocyanin, 200 parts of wolfberry fruit extracts, 100 portions of mannitol, 100 parts Vitamin C, 0.3 part of vitamin A, 6 parts of zinc agent, 400 portions of preservatives, 2000 parts of patch substrates.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the patch is as follows：
1) mass fraction is pressed, by 400 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 20 parts of lutein, 2 parts of zeaxanthins, 10 Part mono maple nervonic acid, 30 portions of anthocyanin, 10 parts of wolfberry fruit extracts, 10 portions of mannitol, 5 parts of vitamin Cs, 0.1 part of vitamin A, 2 The agent of part zinc, 400 portions of preservatives are mixed with 2000 parts of patch substrates heat preservations, obtain mixture C；
2) mass fraction is pressed, step 1), which is obtained mixing C, is applied to back sheet, and is pressed with lid lining, after cutting out, encapsulating Obtain patch.
Embodiment 7 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component：1 Part water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part of mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of vitamin C, 0.02 part of vitamin A, 0.5 part of zinc agent, the dosage form of the product Including drops, patch, pulvis, lozenge, oral solution.
Include following component by pulvis described in mass fraction：1 part of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part of mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of dimension life Plain C, 0.02 part of vitamin A, 0.5 part of zinc agent, 10 parts of soyabean protein powders, 450 parts of soy bean edible fiber powders.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the pulvis is as follows：
1) press mass fraction, by 1 part of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part Mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of vitamin C, 0.02 part of vitamin A, 0.5 part of zinc agent stirs and evenly mixs, and obtains mixture D；
2) mass fraction is pressed, 10 parts of soyabean protein powders, 450 parts of soy bean edible fiber powders are added to the mixed of step 1) acquisition It closes in object D, stirs and evenly mixs, dry, powder processed obtains pulvis.
Embodiment 8 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component： 300 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 20 parts of lutein, 2 parts of zeaxanthins, 20 parts of mono maple nervonic acids, 60 parts of patterns Glycosides, 40 parts of wolfberry fruit extracts, 10 portions of mannitol, 12 parts of vitamin Cs, 0.15 part of vitamin A, 2 parts of zinc agent, the dosage form of the product Including drops, patch, pulvis, lozenge, oral solution.
Include following component by pulvis described in mass fraction：300 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 20 parts of leaf Huangs Element, 2 parts of zeaxanthins, 20 parts of mono maple nervonic acids, 60 portions of anthocyanin, 40 parts of wolfberry fruit extracts, 10 portions of mannitol, 12 parts of dimension lifes Plain C, 0.15 part of vitamin A, 2 parts of zinc agent, 8000 parts of soyabean protein powders, 39000 parts of soy bean edible fiber powders.
It is a kind of prevent, the product of auxiliary treatment disease of eye, the pulvis preparation process is as follows：
1) mass fraction is pressed, by 300 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 20 parts of lutein, 2 parts of zeaxanthins, 20 Part mono maple nervonic acid, 60 portions of anthocyanin, 40 parts of wolfberry fruit extracts, 10 portions of mannitol, 12 parts of vitamin Cs, 0.15 part of vitamin A, 2 parts of zinc agent stir and evenly mix, and obtain mixture D；
2) mass fraction is pressed, 8000 parts of soyabean protein powders, 39000 parts of soy bean edible fiber powders, which are added to step 1), to be obtained Mixture D in, stir and evenly mix, dry, powder processed obtains pulvis.
Embodiment 9 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component： 2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 40 parts of lutein, 40 parts of zeaxanthins, 70 parts of mono maple nervonic acids, 300 parts of flowers Color glycosides, 200 parts of wolfberry fruit extracts, 100 portions of mannitol, 100 parts of vitamin Cs, 0.3 part of vitamin A, 6 parts of zinc agent, the product Dosage form includes drops, patch, pulvis, lozenge, oral solution.
Include following component by pulvis described in mass fraction：2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 40 parts of leaf Huangs Element, 40 parts of zeaxanthins, 70 parts of mono maple nervonic acids, 300 portions of anthocyanin, 200 parts of wolfberry fruit extracts, 100 parts of mannitol, 100 Part vitamin C, 0.3 part of vitamin A, 6 parts of zinc agent, 5000 parts of soyabean protein powders, 45000 parts of soy bean edible fiber powders.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the pulvis is as follows：
1) mass fraction is pressed, by 2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 40 parts of lutein, 4 parts of zeaxanthins, 70 Part mono maple nervonic acid, 300 portions of anthocyanin, 200 parts of wolfberry fruit extracts, 100 portions of mannitol, 100 parts of vitamin Cs, 0.3 part of dimension life Plain A, 6 parts of zinc agent stir and evenly mix, and obtain mixture D；
2) mass fraction is pressed, 5000 parts of soyabean protein powders, 45000 parts of soy bean edible fiber powders, which are added to step 1), to be obtained Mixture D in, stir and evenly mix, dry, powder processed obtains pulvis.
Embodiment 10 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component： 1 part of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part of mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of vitamin C, 0.02 part of vitamin A, 0.5 part of zinc agent, the dosage form of the product Including drops, patch, pulvis, lozenge, oral solution.
Include following component by lozenge described in mass fraction：1 part of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part of mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of dimension life Plain C, 0.02 part of vitamin A, 0.5 part of zinc agent, 0.1 part of magnesium stearate, 0.05 part of citric acid, 10 parts of D-sorbites, 0.01 portion of food Use essence.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the lozenge is as follows：
1) press mass fraction, by 1 part of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 zeaxanthin part, 1 part Mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of vitamin C, 0.02 part of vitamin A, 0.5 part of zinc agent, is stirred mixture E；
2) mass fraction is pressed, by 0.1 part of magnesium stearate, 0.05 part of citric acid, 10 parts of D-sorbites, 0.01 part of food flavor It is added in the mixture E of step 1) acquisition, is stirred tabletting, obtains lozenge.
Embodiment 11 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component： 240 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 4 parts of lutein, 1 part of zeaxanthin, 3 parts of mono maple nervonic acids, 10 portions of anthocyanin, 20 parts of wolfberry fruit extracts, 15 portions of mannitol, 5 parts of vitamin Cs, 0.1 part of vitamin A, 3 parts of zinc agent, the dosage form of the product include Drops, patch, pulvis, lozenge, oral solution.
Include following component by lozenge described in mass fraction：240 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 4 parts of lutein, 1 part of zeaxanthin, 3 parts of mono maple nervonic acids, 10 portions of anthocyanin, 20 parts of wolfberry fruit extracts, 15 portions of mannitol, 5 parts of vitamin Cs, 0.1 part of vitamin A, 3 parts of zinc agent, 5 parts of magnesium stearates, 1 part of citric acid, 750 parts of D-sorbites, 1 part of food flavor.
It is a kind of prevent, the product of auxiliary treatment disease of eye, the preparation process of the lozenge is as follows：
1) by 240 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 4 parts of lutein, 1 zeaxanthin part, 3 parts of acer truncatum nerves Acid, 10 portions of anthocyanin, 20 parts of wolfberry fruit extracts, 15 portions of mannitol, 5 parts of vitamin Cs, 0.1 part of vitamin A, 3 parts of zinc agent, stirring Mixing；
2) 5 parts of magnesium stearates, 1 part of citric acid, 750 parts of D-sorbites, 1 part of food flavor are added to mixed in step 1) It closes in object, is stirred tabletting, obtain the lozenge of a kind of prevention and treatment and auxiliary treatment disease of eye.
Embodiment 12 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component： 800 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 20 parts of lutein, 4 parts of zeaxanthins, 40 parts of mono maple nervonic acids, 100 parts of patterns Glycosides, 100 parts of wolfberry fruit extracts, 50 portions of mannitol, 60 parts of vitamin Cs, 0.2 part of vitamin A, 4 parts of zinc agent, the dosage form of the product Including drops, patch, pulvis, lozenge, oral solution.
Include following component by lozenge described in mass fraction：800 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 20 parts of leaf Huangs Element, 4 parts of zeaxanthins, 40 parts of mono maple nervonic acids, 100 portions of anthocyanin, 100 parts of wolfberry fruit extracts, 50 portions of mannitol, 60 parts of dimensions Raw element C, 0.2 part of vitamin A, 4 parts of zinc agent, 30 parts of magnesium stearates, 15 parts of citric acids, 4500 parts of D-sorbites, 10 parts of edible perfume Essence.
It is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, the preparation process of the lozenge is as follows：
1) mass fraction is pressed, by 800 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 20 parts of lutein, 4 zeaxanthin parts, 40 Part mono maple nervonic acid, 100 portions of anthocyanin, 100 parts of wolfberry fruit extracts, 50 portions of mannitol, 60 parts of vitamin Cs, 0.2 part of vitamin A, 4 parts of zinc agent, are stirred mixture E；
2) mass fraction is pressed, 30 parts of magnesium stearates, 15 parts of citric acids, 4500 parts of D-sorbites, 10 parts of food flavors are added It is added in the mixture E of step 1) acquisition, is stirred tabletting, obtain lozenge.
Embodiment 13 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component： 1 part of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part of mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of vitamin C, 0.02 part of vitamin A, 0.5 part of zinc agent, the dosage form of the product Including drops, patch, pulvis, lozenge, oral solution.
Include following component by oral solution described in mass fraction：1 part of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part of mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of dimension life Plain C, 0.02 part of vitamin A, 0.5 part of zinc agent, 0.5 part of xanthans, 0.5 part of locust bean gum, 0.5 part of carragheen, 0.25 part of anti-corrosion Agent, 5 parts of food flavors, 5000 parts of water.
The product and preparation method thereof of a kind of prevention and treatment and auxiliary treatment disease of eye, the preparation step of the oral solution It is rapid as follows：
1) mass fraction is pressed, 0.5 part of xanthans, 0.5 part of locust bean gum, 0.5 part of carragheen are added in 5000 parts of water, It stirs and evenly mixs, obtains mixture F；
2) press mass fraction, by 1 part of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1 part of lutein, 0.05 part of zeaxanthin, 1 part Mono maple nervonic acid, 1 portion of anthocyanin, 0.5 part of wolfberry fruit extract, 1 portion of mannitol, 0.1 part of vitamin C, 0.02 part of vitamin A, 0.5 part of zinc agent is added in the mixture F of step 1) acquisition, is stirred and evenly mixed, is added 0.25 portion of preservative, 5 parts of food flavors, It stirs and evenly mixs, obtains oral solution.
Embodiment 14
It is a kind of prevent, the product of auxiliary treatment disease of eye, by mass fraction, the product includes following component：320 parts of water Molten Astaxanthin In Haematococcus Pluvialis powder, 2 parts of lutein, 0.5 part of zeaxanthin, 5 parts of mono maple nervonic acids, 10 portions of anthocyanin, 10 parts Wolfberry fruit extract, 5 portions of mannitol, 0.15 part of vitamin C, 0.08 part of vitamin A, 0.8 part of zinc agent, the dosage form of the product include Drops, patch, pulvis, lozenge, oral solution.
Include following component by oral solution described in mass fraction：320 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 2 parts of leaf Huangs Element, 0.5 part of zeaxanthin, 5 parts of mono maple nervonic acids, 10 portions of anthocyanin, 10 parts of wolfberry fruit extracts, 5 portions of mannitol, 0.15 part of dimension Raw element C, 0.08 part of vitamin A, 0.8 part of zinc agent, 4.5 parts of xanthans, 7.5 parts of locust bean gums, 4 parts of carragheens, 24 portions of preservatives, 80 parts of food flavors, 80000 parts of water.
It is a kind of prevent, the product of auxiliary treatment disease of eye, the preparation process of the oral solution is as follows：
1) mass fraction is pressed, 4.5 parts of xanthans, 7.5 parts of locust bean gums, 4 parts of carragheens are added in 80000 parts of water, It stirs and evenly mixs, obtains mixture F；
2) mass fraction is pressed, by 320 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 2 parts of lutein, 0.5 part of zeaxanthin, 5 Part mono maple nervonic acid, 10 portions of anthocyanin, 10 parts of wolfberry fruit extracts, 5 portions of mannitol, 0.15 part of vitamin C, 0.08 part of vitamin A, 0.8 part of zinc agent is added in the mixture F of step 1) acquisition, is stirred and evenly mixed, and 24 portions of preservatives, 80 parts of edible perfume are added Essence stirs and evenly mixs, and obtains oral solution.
Embodiment 15 is a kind of to prevent, the product of auxiliary treatment disease of eye, and by mass fraction, the product includes following component： 2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 40 parts of lutein, 4 parts of zeaxanthins, 70 parts of mono maple nervonic acids, 150 parts of flowers Color glycosides, 100 parts of wolfberry fruit extracts, 80 portions of mannitol, 100 parts of vitamin Cs, 0.3 part of vitamin A, 6 parts of zinc agent, the product Dosage form includes drops, patch, pulvis, lozenge, oral solution.
Include following component by oral solution described in mass fraction：2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 40 parts of leaves Flavine, 4 parts of zeaxanthins, 70 parts of mono maple nervonic acids, 150 portions of anthocyanin, 100 parts of wolfberry fruit extracts, 80 parts of mannitol, 100 Part vitamin C, 0.3 part of vitamin A, 6 parts of zinc agent, 750 parts of xanthans, 750 parts of locust bean gums, 750 parts of carragheens, 250 parts it is anti- Rotten agent, 1000 parts of food flavors, 500000 parts of water.
The product and preparation method thereof of a kind of prevention and treatment and auxiliary treatment disease of eye, the preparation step of the oral solution It is rapid as follows：
1) mass fraction is pressed, 750 parts of xanthans, 750 parts of locust bean gums, 750 parts of carragheens are added to 500000 parts of water In, it stirs and evenly mixs, obtains mixture F；
2) mass fraction is pressed, by 2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 40 parts of lutein, 4 parts of zeaxanthins, 70 Part mono maple nervonic acid, 150 portions of anthocyanin, 100 parts of wolfberry fruit extracts, 80 portions of mannitol, 100 parts of vitamin Cs, 0.3 part of dimension life Plain A, 6 parts of zinc agent are added in the mixture F of step 1) acquisition, are stirred and evenly mixed, add 250 portions of preservatives, 1000 parts it is edible Essence stirs and evenly mixs, and obtains oral solution.
Finally it should be noted that present invention is not limited to the above embodiments, there can also be many variations.This field it is general All deformations that logical technical staff directly can export or associate from present disclosure are considered as the present invention's Protection domain.

Claims (11)

1. the product of a kind of prevention, auxiliary treatment disease of eye, which is characterized in that by mass fraction, the product includes such as the following group Part：1-2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-40 parts of lutein, 0.05-4 parts of zeaxanthins, 1-70 portions of acer truncatums Nervonic acid, 1-300 portions of anthocyanin, 0.5-200 parts of wolfberry fruit extracts, 0-100 portions of mannitol, 0.1-100 parts of vitamin Cs, 0.02- The dosage form of 0.3 part of vitamin A, 0.5-6 parts of zinc agent, the product includes drops, patch, pulvis, lozenge, oral solution.
2. the product of a kind of prevention according to claim 1, auxiliary treatment disease of eye, which is characterized in that press mass parts Number, the drops includes following component：1-100 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-10 parts of lutein, 0.05-2 parts of jade Cream-coloured matter, 1-5 part mono maple nervonic acid, 1-20 portions of anthocyanin, 0.5-4 parts of wolfberry fruit extracts, 0-3 portions of mannitol, 0.1-2 parts of dimensions C, 0.02-0.1 parts of vitamin As of raw element, 0.5-2 parts of zinc agent, 1-100 portions of preservatives, 0.01-15 parts of xanthans, 1000-50000 Part water.
3. it is according to claim 2 it is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, feature exists In the preparation process of the drops is as follows：
1) mass fraction is pressed, 0.01-15 parts of xanthans, 1-100 portions of preservatives are added in 1000-50000 parts of water, stirring is mixed It is even, obtain mixture A；
2) mass fraction is pressed, by 1-100 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-10 parts of lutein, 0.05-2 parts of maize Matter, 1-5 part mono maple nervonic acid, 1-20 portions of anthocyanin, 0.5-4 parts of wolfberry fruit extracts, 0-3 portions of mannitol, 0.1-2 parts of vitamins C, 0.02-0.1 parts of vitamin As, 0.5-2 parts of zinc agent are added to step 1) and obtain in mixture A, stir and evenly mix, and obtain mixture B；
3) the mixture B that step 2) obtains sterilized, packing, labelled, obtain drops.
4. the product of a kind of prevention according to claim 1, auxiliary treatment disease of eye, which is characterized in that press mass parts Number, the patch includes following component：1-400 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-20 parts of lutein, 0.05-2 parts of jade Cream-coloured matter, 1-10 part mono maple nervonic acid, 1-30 portions of anthocyanin, 0.5-10 parts of wolfberry fruit extracts, 0-10 parts of mannitol, 0.1-5 Part vitamin C, 0.02-0.1 parts of vitamin As, 0.5-2 parts of zinc agent, 1-400 portions of preservatives, 1-2000 parts of patch substrates.
5. it is according to claim 4 it is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, feature exists In the preparation process of the patch is as follows：
1) mass fraction is pressed, by 1-400 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-20 parts of lutein, 0.05-2 parts of maize Matter, 1-10 part mono maple nervonic acid, 1-30 portions of anthocyanin, 0.5-10 parts of wolfberry fruit extracts, 0-10 portions of mannitol, 0.1-5 parts of dimensions C, 0.02-0.1 parts of vitamin As of raw element, 0.5-2 parts of zinc agent, 1-400 portions of preservatives are mixed with 1-2000 parts of patch substrate heat preservations, Obtain mixture C；
2) press mass fraction, step 1), which is obtained mixing C, is applied to back sheet, and is pressed with lid lining, cut out, encapsulate after obtain Patch.
6. it is according to claim 1 it is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, feature exists In by mass fraction, the pulvis includes following component：1-2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-40 parts of leaves are yellow Element, 0.05-4 parts of zeaxanthins, 1-70 parts of mono maple nervonic acids, 1-300 portions of anthocyanin, 0.5-200 parts of wolfberry fruit extracts, 0- 100 portions of mannitol, 0.1-100 parts of vitamin Cs, 0.02-0.3 parts of vitamin As, 0.5-6 parts of zinc agent, 10-5000 portions of soybean proteins Powder, 100-45000 part soy bean edible fiber powder.
7. it is according to claim 6 it is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, feature exists In the preparation process of the pulvis is as follows：
1) mass fraction is pressed, by 1-2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-40 parts of lutein, 0.05-4 parts of maize Matter, 1-70 part mono maple nervonic acid, 1-300 portions of anthocyanin, 0.5-200 parts of wolfberry fruit extracts, 0-100 parts of mannitol, 0.1-100 Part vitamin C, 0.02-0.3 parts of vitamin As, 0.5-6 parts of zinc agent stir and evenly mix, and obtain mixture D；
2) mass fraction is pressed, 10-5000 parts of soyabean protein powders, 450-45000 parts of soy bean edible fiber powders are added to step 1) It in the mixture D of acquisition, stirs and evenly mixs, dry, powder processed obtains pulvis.
8. it is according to claim 1 it is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, feature exists In by mass fraction, the lozenge includes following component：1-800 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-20 parts of leaves are yellow Element, 0.05-4 parts of zeaxanthins, 1-40 parts of mono maple nervonic acids, 1-100 portions of anthocyanin, 0.5-100 parts of wolfberry fruit extracts, 0-50 Part mannitol, 0.1-60 parts of vitamin Cs, 0.02-0.2 parts of vitamin As, 0.5-4 parts of zinc agent, 0.1-30 parts of magnesium stearates, 0.05- 15 parts of citric acids, 10-4500 parts of D-sorbites, 0.01-10 parts of food flavors.
9. it is according to claim 8 it is a kind of prevent, the preparation method of the product of auxiliary treatment disease of eye, feature exists In the preparation process of the lozenge is as follows：
1) mass fraction is pressed, by 1-800 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-20 parts of lutein, 0.05-4 zeaxanthins Part, 1-40 parts of mono maple nervonic acids, 1-100 portions of anthocyanin, 0.5-100 parts of wolfberry fruit extracts, 0-50 portions of mannitol, 0.1-60 parts Vitamin C, 0.02-0.2 part vitamin A, 0.5-4 parts of zinc agent, are stirred mixture E；
2) mass fraction is pressed, by 0.1-30 parts of magnesium stearates, 0.05-15 parts of citric acids, 10-4500 parts of D-sorbites, 0.01-10 Part food flavor is added in the mixture E of step 1) acquisition, is stirred tabletting, obtains lozenge.
10. the product and preparation method thereof of a kind of prevention and treatment according to claim 1 and auxiliary treatment disease of eye, It is characterized in that, pressing mass fraction, the oral solution includes following component：1-2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-40 parts of lutein, 0.05-4 parts of zeaxanthins, 1-70 parts of mono maple nervonic acids, 1-150 portions of anthocyanin, 0.5-100 portions of matrimony vines Extract, 0-80 portion mannitol, 0.1-100 parts of vitamin Cs, 0.02-0.3 parts of vitamin As, 0.5-6 parts of zinc agent, 0.5-750 parts Xanthans, 0.5-750 part locust bean gum, 0.5-750 parts of carragheens, 0.25-250 portions of preservatives, 5-1000 parts of food flavors, 5000-500000 parts of water.
11. product and its preparation side of a kind of prevention and treatment according to claim 10 and auxiliary treatment disease of eye Method, which is characterized in that the preparation process of the oral solution is as follows：
1) mass fraction is pressed, 0.5-750 parts of xanthans, 0.5-750 parts of locust bean gums, 0.5-750 parts of carragheens are added to It in 5000-500000 parts of water, stirs and evenly mixs, obtains mixture F；
2) mass fraction is pressed, by 1-2000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis powder, 1-40 parts of lutein, 0.05-4 parts of maize Matter, 1-70 part mono maple nervonic acid, 1-150 portions of anthocyanin, 0.5-100 parts of wolfberry fruit extracts, 0-80 parts of mannitol, 0.1-100 Part vitamin C, 0.02-0.3 parts of vitamin As, 0.5-6 parts of zinc agent are added in the mixture F of step 1) acquisition, are stirred and evenly mixed, 0.25-250 portions of preservatives, 5-1000 parts of food flavors are added, are stirred and evenly mixed, oral solution is obtained.
CN201810460967.6A 2018-05-15 2018-05-15 It is a kind of prevent, the product and preparation method thereof of auxiliary treatment disease of eye Pending CN108634303A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810460967.6A CN108634303A (en) 2018-05-15 2018-05-15 It is a kind of prevent, the product and preparation method thereof of auxiliary treatment disease of eye

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810460967.6A CN108634303A (en) 2018-05-15 2018-05-15 It is a kind of prevent, the product and preparation method thereof of auxiliary treatment disease of eye

Publications (1)

Publication Number Publication Date
CN108634303A true CN108634303A (en) 2018-10-12

Family

ID=63755511

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810460967.6A Pending CN108634303A (en) 2018-05-15 2018-05-15 It is a kind of prevent, the product and preparation method thereof of auxiliary treatment disease of eye

Country Status (1)

Country Link
CN (1) CN108634303A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110037218A (en) * 2019-05-06 2019-07-23 云南爱尔康生物技术有限公司 Improve the haematococcus pluvialis lutein solid drink and preparation method thereof of visual fatigue
CN113331420A (en) * 2021-06-21 2021-09-03 北京兰厚化妆品有限责任公司 Composition for protecting eyes, health food and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106038612A (en) * 2016-06-29 2016-10-26 北京康力基生物科技有限公司 Pharmaceutical composition for protecting eyesight as well as preparation method and application thereof
CN106692259A (en) * 2015-11-16 2017-05-24 浙江医药股份有限公司新昌制药厂 Composition for improving glare stimulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692259A (en) * 2015-11-16 2017-05-24 浙江医药股份有限公司新昌制药厂 Composition for improving glare stimulation
CN106038612A (en) * 2016-06-29 2016-10-26 北京康力基生物科技有限公司 Pharmaceutical composition for protecting eyesight as well as preparation method and application thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110037218A (en) * 2019-05-06 2019-07-23 云南爱尔康生物技术有限公司 Improve the haematococcus pluvialis lutein solid drink and preparation method thereof of visual fatigue
CN113331420A (en) * 2021-06-21 2021-09-03 北京兰厚化妆品有限责任公司 Composition for protecting eyes, health food and preparation method thereof

Similar Documents

Publication Publication Date Title
JP2009013146A (en) Diabetes treating composition
CN102617897A (en) Preparation method of rubber gloves containing natural vanilla extracts
CN108634303A (en) It is a kind of prevent, the product and preparation method thereof of auxiliary treatment disease of eye
CN102894405B (en) Antihypertensive and health-care clam crisp and processing method thereof
KR101617320B1 (en) Royal jelly beverage composition having improved dispersability in water and method for preparing the same
CN108260787A (en) Eyeshield health-care fruit jelly and its manufacturing method
KR20170133934A (en) Manfacturing method of functional crust of overcooked rice food comprising aronia
KR20050014614A (en) A beans as vinegar use of fermataion method and a beans paste of manufacturing process
CN108740973A (en) A kind of pure natural rose paste and preparation method thereof
CN103931796A (en) Liver and kidney nourishing peanut oil and its preparation method
KR20030077215A (en) Denatured Spirulina and manufacturing method thereof
KR101897591B1 (en) Anti-oxidative activity berry beverage containing solidity materials and manufacturing method thereby
KR20170079340A (en) Swelling calves relief patch and manufacturing method of same
CN106701440A (en) Brewing method of South Shaanxi walnut wine
KR101715879B1 (en) Method for cooking duck stew and duck stew by the method
KR101833389B1 (en) The method of Ainsliaea fragrans-containing noodles and noodles made thereby
CN110150631A (en) A kind of thick chilli sauce and preparation method thereof
CN109418845A (en) A kind of fragrant spicy konjak snack food and its production technology
KR102001345B1 (en) Preparation method of aronia tofu with masked astringent taste
CN107873889A (en) Red bean milk tea
KR102486555B1 (en) powder type natural seasoning composition comprising yeast extract
KR20090037155A (en) Tropical fruit-flavored mixed tea with excellent preference and preparing method thereof
KR20180039473A (en) Laver Jam and Preparation methods thereof
KR20170116523A (en) preparation method of yakju (Korean cleared rice wine) and takju (Korean turbid rice wine) fermented by addition lacquer extracts
CN105433109A (en) Making method of mung bean soy sauce

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20181012

RJ01 Rejection of invention patent application after publication